CASI Pharmaceuticals Receives EU Orphan Drug Designation for ENMD-2076 To Treat Hepatocellular Carcinoma Including...

Casi Pharmaceuticals, a biopharmaceutical company based in Rockville, MD, announced that its oncology drug candidate, ENMD-2076, has received Orphan Drug designation (ODD) from the European Medicines Agency (EMA) for the treatment...

Rebiotix Receives Breakthrough Therapy Designation for RBX2660 – A Microbiota Restoration Therapy (MRT) for...

Rebiotix Inc., a biotechnology company based in Roseville, MN, announced that the U.S. FDA has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of...

BMS’ Opdivo (nivolumab) Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer...

Bristol-Myers Squibb, a pharmaceutical company headquartered in New York City, received approval from U.S FDA for its Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic non-small...

Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib – a CDK 4 and 6...

Eli Lilly, a global pharmaceutical company headquartered in Indianapolis, announced that the U.S FDA has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients...

Tarix Orphan Receives FDA Fast Track Designation for TXA127 as Potential Treatment for Duchenne...

Tarix Orphan, a private biopharmaceutical company based in Cambridge, MA, announced that the U.S. FDA has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal  muscle damage and fibrosis...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Expands Site in the United States for Drug Development...

We are pleased to announce the grand opening of WuXi AppTec's expanded Laboratory Testing Division (LTD) facility in New Jersey. The expansion will double total...